Brief: Cabaletta Bio Unaudited Cash, Cash Equivalents And Short-Term Investments As Of Dec. 31, 2023 Was $241 Mln
08/01/2024 14:21
Jan 8 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO INC: UNAUDITED CASH, CASH EQUIVALENTS AND
SHORT-TERM INVESTMENTS AS OF DECEMBER 31, 2023 WAS $241 MILLION
Source text for Eikon: ID:
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity